37 completed, 9 recruiting, 5 active not recruiting, 4 unknown. 61 Phase 2, 10 Phase 1, 5 Phase 3.
Follow Ono Pharmaceutical Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of DCC-3014 to Evaluate the Efficacy, Safety, and Pharmacokinetics in Subjects With TGCT DCC-3014 - Tenosynovial Giant Cell Tumor | Phase 2 | Not yet recruiting | Ono Pharmaceutical Co., Ltd. | 18 | 2026-10-31 | 2026-09-22 |
| ONO-4915 in Patients With Primary Sjogren's Disease ONO-4915, Placebo - Sjogren's Disease | Phase 2 | Not yet recruiting | Ono Pharmaceutical Co., Ltd. | 60 | 2026-10-01 | 2026-09-16 |
| A Study of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma. ONO-4538HSC - Pediatric Malignant Solid Tumor and Epithelioid Sarcoma | Phase 1 / Phase 2 | Recruiting | Ono Pharmaceutical Co., Ltd. | 50 | 2026-09-15 | 2026-10-06 |
| ONO-4538 Study in Patients With Richter's Transformation ONO-4538 - Richter's Transformation | Phase 2 | Recruiting | Ono Pharmaceutical Co., Ltd. | 14 | 2025-11-19 | 2026-02-13 |
| A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer ONO-4578, Opdivo®, Oxaliplatin - Colorectal Cancer | Phase 2 | Recruiting | Ono Pharmaceutical Co., Ltd. | 144 | 2025-11-18 | 2026-07-16 |
| A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease Dementia ONO-2020, Placebo - Agitation Associated With Alzheimer's Disease Dementia | Phase 2 | Recruiting | Ono Pharmaceutical Co., Ltd. | 90 | 2025-05-01 | 2026-09-25 |
| A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease ONO-2020, Placebo - Alzheimer Disease | Phase 2 | Completed | Ono Pharmaceutical Co., Ltd. | 260 | 2025-04-24 | 2026-10-22 |
| A Clinical Study of ONO-1110 in Patients With Hunner Type Interstitial Cystitis ONO-1110, Placebo - Hunner Type Interstitial Cystitis | Phase 2 | Completed | Ono Pharmaceutical Co., Ltd. | 57 | 2025-04-02 | 2026-07-07 |
| A Clinical Study of ONO-1110 in Patients With Fibromyalgia ONO-1110, Placebo - Fibromyalgia | Phase 2 | Completed | Ono Pharmaceutical Co., Ltd. | 175 | 2025-03-26 | 2026-07-07 |
| A Study of ONO-1110 in Patients With Postherpetic Neuralgia ONO-1110, Placebo - Postherpetic Neuralgia | Phase 2 | Completed | Ono Pharmaceutical Co., Ltd. | 142 | 2025-02-12 | 2026-07-15 |
| A Study of ONO-1110 in Patients With Social Anxiety Disorder ONO-1110, Placebo - Social Anxiety Disorder (SAD) | Phase 2 | Completed | Ono Pharmaceutical Co., Ltd. | 115 | 2025-01-31 | 2026-07-08 |
| A Study of ONO-1110 in Patients With Major Depressive Disorder ONO-1110, Placebo - Major Depressive Disorder (MDD | Phase 2 | Completed | Ono Pharmaceutical Co., Ltd. | 103 | 2025-01-16 | 2026-07-08 |
| Study to ONO-4538 in Patients With Rhabdoid Tumor ONO-4538 - Rhabdoid Tumor | Phase 2 | Recruiting | Ono Pharmaceutical Co., Ltd. | 23 | 2024-11-25 | 2026-08-04 |
| A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) ONO-4578, Oxaliplatin, Capecitabine - Gastric Cancer | Phase 2 | Active not recruiting | Ono Pharmaceutical Co., Ltd. | 226 | 2024-01-10 | 2026-03-13 |
| Tirabrutinib Maintenance Versus Placebo in Patients With Primary CNS Lymphoma in Complete Remission (JCOG2104) Tirabrutinib, Placebo - Primary Central Nervous System Lymphoma | Phase 2 | Recruiting | Kyorin University | 92 | 2023-10-06 | 2026-08-05 |
| A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy ONO-2808, Placebo - Multiple System Atrophy (MSA) | Phase 2 | Active not recruiting | Ono Pharmaceutical Co., Ltd. | 92 | 2023-09-22 | 2026-10-06 |
| Study to Investigate the Chemotherapy-Induced Peripheral Neuropathy (CIPN) Onset-Suppressing Effect and Safety of ONO-2910 in Patients With Breast Cancer Receiving Weekly Paclitaxel ONO-2910, Placebo - CIPN - Chemotherapy-Induced Peripheral Neuropathy | Phase 2 | Completed | Ono Pharmaceutical Co., Ltd. | 210 | 2023-08-31 | 2025-04-03 |
| Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume) Binimetinib 15 MG - Low-grade Glioma, Pancreatic Cancer | Phase 2 | Recruiting | National Cancer Center, Japan | 32 | 2023-03-29 | 2023-12-13 |
| Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures Cenobamate - Epilepsies, Partial | Phase 2 | Recruiting | Ono Pharmaceutical Co., Ltd. | 100 | 2022-11-04 | 2025-06-03 |
| Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study) Tirabrutinib - Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma | Phase 2 | Active not recruiting | Ono Pharmaceutical Co., Ltd. | 119 | 2021-12-29 | 2026-03-30 |
Showing 20 of 61. Sign in to see all of them.
Neoplasms (3) · Stomach Neoplasms (3) · Urinary Bladder, Overactive (3) · Amyotrophic Lateral Sclerosis (2) · Asthma (2) · Colorectal Neoplasms (2) · Coronary Artery Disease (2) · Pancreatic Neoplasms (2) · Sjogren's Syndrome (2) · Alzheimer Disease (1) · COVID-19 (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Community-Acquired Pneumonia (1) · Dementia (1)
Nivolumab (22) · Ipilimumab (5) · Oxaliplatin (5) · Capecitabine (4) · Bevacizumab (3) · S 1 (combination) (3) · landiolol (3) · tirabrutinib (3) · Fluorouracil (2) · Leucovorin (2) · gemilukast (2) · montelukast (2) · Aprepitant (1) · Cenobamate (1) · Cetirizine (1)
Japan (39) · United States (16) · Canada (8) · Germany (8) · Spain (8) · South Korea (7) · Taiwan (7) · United Kingdom (7) · France (6) · Italy (6) · Belgium (5) · Poland (5) · Czechia (4) · Netherlands (4) · Hungary (3)
Project Leader (20) · Project Leader, Development Planning (5) · Tomohiro Kuwayama (3) · Mitsunobu Tanimoto (2) · Arya Mani, MD (1) · Hitoshi Kajitani (1) · Iwao Sugitani, MD, PhD (1) · Jong-Mu Sun (1) · Ken Kato, M.D. / Ph.D. (1) · Koji Takehara (1)
PMID 20718754, PMID 23547081, PMID 23784548, PMID 26446770, PMID 27444660, PMID 27649982, PMID 28131785, PMID 28434648, PMID 29119276, PMID 30170630, PMID 30566590, PMID 31176752, PMID 31487218, PMID 32094063, PMID 32324435, PMID 32710922, PMID 33001135, PMID 34051329, PMID 34083421, PMID 35030335, PMID 35377447, PMID 36323435, PMID 36512738, PMID 36852452, PMID 38295160, PMID 38340723, PMID 38485190, PMID 38608691, PMID 38834744, PMID 39162872, PMID 39516370, PMID 39889250, PMID 41113977, PMID 41385448, PMID 41766168, PMID 42223130, PMID 42821736
2016 (5), 2015 (1), 2017 (1)